What's in TG Therapeutics, Inc.'s pipeline?

TG Therapeutics, Inc. has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with TG Therapeutics, Inc.'s portfolio?

Top competitors by shared drug class: , AMGEN INC, CELLTRION INC, Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tg-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

TG Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TG Therapeutics, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
BRIUMVI	UBLITUXIMAB-XIIY	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	Neuroscience

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
AMGEN INC · 1 shared drug class
CELLTRION INC · 1 shared drug class
Roche · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TG Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). TG Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tg-therapeutics-inc. Accessed 2026-05-16.